“`html
Hologic, Inc. (HOLX) announced that its HOLX Genius Digital Diagnostics System has received expanded CE marking in the European Union, enhancing its capabilities for imaging and reviewing both cell and tissue specimens. This system, previously limited to cell analysis used mainly in cervical cancer screening, now offers added software features like remote support and laboratory information system readiness, aiming to improve operational efficiency and diagnostic accuracy across European labs.
In fiscal Q4 2025, Hologic’s cytology and perinatal businesses grew by 5.7% year over year, driven by the rollout of the Genius Digital Diagnostics System. Over the past six months, Hologic’s shares have increased by 34.8%, outperforming the industry average growth of 13.9%. The company’s forward five-year price-to-sales ratio stands at 3.86, below the industry average of 4.40.
“`
